|
Frank
TS et al. Clinical characteristics of individuals with
germline mutations in BRCA1 and BRCA2: analysis of 10,000
individuals. J Clin Oncol. 2002 Mar 15;20(6):1480-90. PubMed
abstract.
Frank
TS, Braverman AM. The pros and cons of genetic testing
for breast and ovarian cancer risk. Int J Fertil Womens
Med. 1999;44:139-145. PubMed
abstract.
Gail
MH, et al. Projecting individualized probabilities of
developing breast cancer for white females who are being
examined annually. J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
PubMed
abstract
Hall
MA, Rich SS. Patients' fear of genetic discrimination
by health insurers: the impact of legal protections.
Genet Med. 2000 Jul-Aug;2(4):207-8 PubMed
abstract.
Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of
bilateral prophylactic mastectomy in women with a family
history of breast cancer. N
Engl J Med. 1999;340(2):77-84. PubMed
abstract
Hartmann LC, Schaid D, Sellers T, et al. Bilateral prophylactic
mastectomy (PM) in BRCA1/2 mutations carriers.
Proc Am Assoc Canc Res. 2000;41:222-223.
Kash
KM, et al. Psychosocial aspects of cancer genetics:
women at high risk for breast and ovarian cancer. Semin
Surg Oncol. 2000;18:333-338. PubMed
abstract
Lerman
C, Narod S, Schulman K, et al. BRCA1 testing in families
with hereditary breast-ovarian cancer. A prospective
study of patient decision making and outcomes. JAMA.
1996;275(24):1885-1892. (JAMA published earlier than
1998 not available online). PubMed abstract
Mammographic
Screening for Asymptomatic Women (AMA CSA Report)
McCarthy
Veach P, Bartels DM, LeRoy BS. Ethical and professional
challenges posed by patients with genetic concerns:
a report of focus group discussions with genetic counselors,
physicians, and nurses. J Genet Counsel. 10(2):2001;97-119.
Meijers-Heijboer
H, van Geel B, van Putten WL, et al. Breast cancer after
prophylactic bilateral mastectomy in women with a BRCA1
or BRCA2 mutation. N
Engl J Med. 2001 Jul 19;345(3):159-64. Pub
Med Abstract
|
